Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Med Chir Soc Med Nat Iasi ; 116(2): 425-31, 2012.
Article in English | MEDLINE | ID: mdl-23077931

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of liver disease from steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. Most NAFLD patients are hyperinsulinaemic and more insulin resistant compared with nonsteatotic healthy subjects, and there is a near universal association between NAFLD and insulinresistance (IR) irrespective of obesity. The metabolic syndrome (MS) is highly prevalent in the general adult population (approximatively 22%) and it carries an increased cardiovascular morbidity and mortality. Pathophysiologic considerations, clinical associations, and laboratory investigations support that IR and hyperinsulinaemia have a central role in pathogenesis of both MS and NAFLD. The fatty liver is resistant to the action of insulin to suppress hepatic glucose production, which results in hyperglycaemia and, further, in hyperinsulinemia. The MS is associated with maldistribution of body fat, increased free fatty acids (FFAs) and IR, leading to type 2 diabetes, hypertension, dyslipidemia. Visceral fat is an important clinical marker of metabolic cardiovascular risk and a marker of IR in multiple tissues, independent of body mass index (BMI). NAFLD and atherosclerosis share common molecular mediators and NAFLD itself might play an early role in the development and progression of atherosclerosis. These data suggest that NAFLD should be considered part of a multi-organ system derangement in insulin sensitivity, and help explain why NAFLD is so closely linked with diabetes, MS and is an important risk factor for coronary heart disease. NAFLD may be the hepatic manifestation of the MS and raises the possibility that it may play an early role in the etiology of MS.


Subject(s)
Fatty Liver/complications , Metabolic Syndrome/etiology , Adipose Tissue , Body Mass Index , Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/etiology , Fatty Liver/epidemiology , Fatty Liver/metabolism , Humans , Metabolic Syndrome/complications , Metabolic Syndrome/epidemiology , Metabolic Syndrome/metabolism , Non-alcoholic Fatty Liver Disease , Prevalence , Risk Factors , Romania/epidemiology
2.
Rev Med Chir Soc Med Nat Iasi ; 116(3): 692-9, 2012.
Article in English | MEDLINE | ID: mdl-23272512

ABSTRACT

AIM: To evaluate the prevalence of steatosis and to assess its correlations with the classical cardiovascular (CV) risk factors, components of metabolic syndrome (MS) in a rural population. MATERIAL AND METHODS: A sample of 254 subjects was enrolled in the study. Collected data included: age, gender, complete medical history, anthropometric and blood pressure (BP) measurements. The biological evaluation included metabolic and hepatic parameters. Ultrasound evaluation of steatosis relied on the criteria of the National Health and Nutrition Examination Survey (NHANES) III. RESULTS: Two thirds of the study population were obese or overweight (64.96%); 32.66% had systolic BP and 27.16% diastolic BP levels higher than normal. 38% of the subjects had abnormal fasting blood glucose levels, 14.56% having glycated hemoglobin (HbA1c) values corresponding to pre-diabetes, and 9.84% to overt diabetes; 8% had low HDL-cholesterol and 14.96% high triglycerides (Tg) levels. MS was present in 50.8% of individuals. Only 10.8% of all subjects did not have an ultrasound appearance of steatosis; 28.8% had moderate and 32% severe steatosis. There were statistically significant differences in subjects with steatosis vs. subjects without steatosis with regard to body mass index (BMI), WC, presence of MS, and BP and Tg levels, but not to ALAT, ASAT and GGT values. CONCLUSIONS: The important prevalence of obesity, fasting hyperglycamia, steatosis and MS shows a particularly metabolic fragile population; early diagnosis and interventional strategies are mandatory.


Subject(s)
Cardiovascular Diseases/complications , Fatty Liver/complications , Metabolic Syndrome/complications , Obesity/complications , Adult , Aged , Biomarkers/blood , Blood Pressure Determination , Body Mass Index , Cardiovascular Diseases/blood , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/physiopathology , Cholesterol, HDL/blood , Cross-Sectional Studies , Early Diagnosis , Fatty Liver/blood , Fatty Liver/epidemiology , Fatty Liver/physiopathology , Female , Glucose Tolerance Test/methods , Glycated Hemoglobin/metabolism , Humans , Male , Metabolic Syndrome/blood , Metabolic Syndrome/epidemiology , Metabolic Syndrome/physiopathology , Middle Aged , Non-alcoholic Fatty Liver Disease , Obesity/blood , Obesity/epidemiology , Obesity/physiopathology , Overweight/complications , Prevalence , Risk Assessment , Risk Factors , Romania/epidemiology , Rural Population/statistics & numerical data , Sampling Studies , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...